TrialDrug design, development and therapy2025
Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects.
Jaegu Kang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.